Kidney Cancer最新文献

Comparison of Oncological and Functional Outcomes of Radical Versus Partial Nephrectomy for cT1b Renal Cell Carcinoma: A Two-Centre, Matched Analysis cT1b 肾细胞癌根治性肾切除术与部分肾切除术的肿瘤学和功能性疗效比较：双中心匹配分析

IF 1.2

Kidney Cancer Pub Date : 2024-02-29 DOI: 10.3233/kca-230019

L. van den Brink, D.L. van den Kroonenberg, N. Graafland, Axel Bex, H. Beerlage, J. R. van Moorselaar, Patricia Zondervan

{"title":"Comparison of Oncological and Functional Outcomes of Radical Versus Partial Nephrectomy for cT1b Renal Cell Carcinoma: A Two-Centre, Matched Analysis","authors":"L. van den Brink, D.L. van den Kroonenberg, N. Graafland, Axel Bex, H. Beerlage, J. R. van Moorselaar, Patricia Zondervan","doi":"10.3233/kca-230019","DOIUrl":"https://doi.org/10.3233/kca-230019","url":null,"abstract":"BACKGROUND: It remains unclear which patients with cT1b renal cell carcinoma (RCC) benefit most from partial nephrectomy (PN) versus radical nephrectomy (RN) considering oncological outcomes and renal function. OBJECTIVE: To compare oncological and functional outcomes of RN with PN for cT1b RCC. METHODS: This is a retrospective analysis of patients who underwent RN or PN for cT1b between 2010 and 2022 (n = 241). Patients were grouped by RN or PN and matched by age, sex, Charlson Comorbidity Index, BMI, PADUA score, RENAL score, ASA score, and preoperative kidney function (eGFR) using propensity score matching. The 10-year overall survival (OS), 10-year cancer-specific survival (CSS), and 10-year recurrence-free survival (RFS) were compared. Change in eGFR from baseline to 5-year follow-up was assessed. RESULTS: After matching, 100 patients remained in each group for analysis. The 10-year OS, CSS, and RFS rates were similar between groups. For patients classified as low risk, the PN group displayed a higher recurrence rate compared to RN (7 vs. 0, p = 0.01). Patients who underwent RN had worse 1-year postoperative eGFR than PN (RN: 57 [44–65], PN: 73 [60–87], p < 0.001). RN was more likely to induce new-onset chronic kidney disease (CKD) stage ≥3b compared to PN (p < 0.001). Complication rate after PN was significantly higher (p = 0.003). CONCLUSION: 10-year survival rates were similar, despite more recurrences in the PN group. Our data shows that post-surgical renal function is superior for PN. Nevertheless, RN is a reliable treatment option when preservation of renal function is not a priority.","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140410929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Trials Corner: Is the Era of Theranostics Imminent? 临床试验角：疗法时代即将到来？

IF 1.2

Kidney Cancer Pub Date : 2024-02-20 DOI: 10.3233/kca-239003

M. Parikh

引用次数: 0

Clinical Trials Corner: The dreaded IVC thrombus - optimizing management 临床试验角：可怕的 IVC 血栓--优化管理

IF 1.2

Kidney Cancer Pub Date : 2024-02-20 DOI: 10.3233/kca-239004

M. Parikh

引用次数: 0

Molecularly Defined Renal Carcinomas 分子定义的肾癌

IF 1.2

Kidney Cancer Pub Date : 2024-02-16 DOI: 10.3233/kca-230015

Marta Amann-Arévalo, Pablo Ballestín Martínez, Natalia Vidal Cassinello, Ignacio Moreno Perez, Montserrat de la Torre-Serrano, Javier Puente

{"title":"Molecularly Defined Renal Carcinomas","authors":"Marta Amann-Arévalo, Pablo Ballestín Martínez, Natalia Vidal Cassinello, Ignacio Moreno Perez, Montserrat de la Torre-Serrano, Javier Puente","doi":"10.3233/kca-230015","DOIUrl":"https://doi.org/10.3233/kca-230015","url":null,"abstract":"RCC has witnessed a significant increase in its incidence over the last five decades, ranking as the ninth most common cancer globally. Although survival rates have improved substantially, RCC remains one of the deadliest urological cancers. Traditionally, RCC subtypes were classified based on histopathological features. However, in recent years, there has been a paradigm shift towards molecular and genomic characterization of RCC, leading to the recognition of distinct molecular subtypes. The 2022 World Health Organization (WHO) classification introduced a new category called “molecularly defined renal carcinomas,” encompassing various subtypes, including SMARCB1-deficient medullary carcinoma, ALK-rearranged RCC, FH-deficient RCC, SDH-deficient RCC, ELOC-mutated RCC, TFEB-altered RCC, and TFE3-rearranged RCC. These molecular subgroups have significant consequences for diagnosis, prognosis, and treatment. Molecularly defined RCCs are frequently underrepresented in clinical trials, encouraging additional research to identify beneficial therapeutics. Immune checkpoint inhibitors and tyrosine- kinase inhibitors have shown promising results in some subtypes, while others may benefit from specific inhibitors targeting their molecular drivers. Additionally, these classifications have important prognostic implications, guiding treatment decisions and genetic counseling.","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139961656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Targeted Radiation Therapy in the Treatment of Renal Cell Carcinoma 靶向放射治疗在肾细胞癌治疗中的作用

IF 1.2

Kidney Cancer Pub Date : 2024-02-16 DOI: 10.3233/kca-230020

Albert Lee, Karie D. Runcie, James B. Yu

引用次数: 0

Emerging Antibody-Drug Conjugate Therapies and Targets for Metastatic Renal Cell Carcinoma 转移性肾细胞癌的新兴抗体药物共轭疗法和靶点

IF 1.2

Kidney Cancer Pub Date : 2023-12-29 DOI: 10.3233/kca-230012

Harrison C. Gottlich, Reza Nabavizadeh, Mihai Dumbrava, Rodrigo Rodrigues Pessoa, Ahmed M. Mahmoud, Ishita Garg, Jacob J. Orme, B. A. Costello, John Cheville, Fabrice Lucien

{"title":"Emerging Antibody-Drug Conjugate Therapies and Targets for Metastatic Renal Cell Carcinoma","authors":"Harrison C. Gottlich, Reza Nabavizadeh, Mihai Dumbrava, Rodrigo Rodrigues Pessoa, Ahmed M. Mahmoud, Ishita Garg, Jacob J. Orme, B. A. Costello, John Cheville, Fabrice Lucien","doi":"10.3233/kca-230012","DOIUrl":"https://doi.org/10.3233/kca-230012","url":null,"abstract":"Background: Approximately 30% of renal cell carcinoma (RCC) cases present with de novo metastatic disease, while 20% to 30% of those with localized disease will develop metastases following surgical resection. Various drug classes have been investigated to treat RCC, including cytokine-based therapies, small molecule Vascular Endothelial Growth Factor (VEGF) tyrosine kinase inhibitors (TKIs) and antibody-based therapies. Up to 58% of patients fail to respond to primary immune checkpoint inhibitor (ICI) therapy, and nearly all initial responders experience disease progression due to the development of secondary resistance. Consequently, novel treatment options are being investigated. Objective: Review the rapidly evolving ADC therapeutic landscape in metastatic RCC including recent trials, emerging ADCs targets, and future directions for ADCs in the treatment of advanced RCC. Methods: Literature review using the MEDLINE database on important trials and presentations from the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO) conferences. Key words used included “renal cell carcinoma,” “RCC,” “metastatic RCC,” “advanced RCC,” “antibody-based therapies,” “immunotherapy,” “clinical trials,” and “emerging drugs.” Specifically for review of ADCs in RCC, the following search string was used with additional review of bibliographies from retrieved papers: “((antibody drug conjugate) OR (antibody-dependent cellular cytotoxicity) OR (chimeric antigen receptor)) AND ((kidney cancer) OR (renal cell carcinoma))”. Results: Several promising targets including MMP14, EGFR, MCT4, CA9, MET, CDH13, B7-H3, and PSMA were identified with relevant preclinical and clinical studies reviewed. Conclusions: While ADCs therapeutics have not shown benefit to date for renal cell carcinoma, there are ample promising candidates and targets for future research.","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139144541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nephrotoxicity Associated with Contemporary Renal Cell Carcinoma Regimens: A Systematic Review and Meta-Analysis 与当代肾细胞癌治疗方案相关的肾毒性：系统回顾与元分析

IF 1.2

Kidney Cancer Pub Date : 2023-12-18 DOI: 10.3233/kca-230018

Akasha Dukkipati, Xiaochen Li, S. Pal, Miguel Zugman

{"title":"Nephrotoxicity Associated with Contemporary Renal Cell Carcinoma Regimens: A Systematic Review and Meta-Analysis","authors":"Akasha Dukkipati, Xiaochen Li, S. Pal, Miguel Zugman","doi":"10.3233/kca-230018","DOIUrl":"https://doi.org/10.3233/kca-230018","url":null,"abstract":"Background: The nephrotoxicity profile of contemporary first-line regimens for treatment of metastatic renal cell carcinoma (mRCC) has not been systematically studied in published clinical trials. Objective: To assess the rates of nephrotoxic events of contemporary first-line regimens for treatment of mRCC in comparison to vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI) mono-therapy. Methods: We performed a systematic search of the literature looking for randomized clinical trials that contemplated National Comprehensive Cancer Network (NCCN) recommended first-line regimens for treating mRCC in which the control arm was a VEGF-TKI. Selected trials could either include an experimental arm of immune checkpoint inhibitor (ICI) plus VEGF-TKI combination or ICI-ICI combination. Nephrotoxic events were defined as proteinuria, hypertension, blood creatinine increase, acute kidney failure or nephritis, which were all described separately. Results: Five studies satisfied our inclusion criteria. Combination of ICI with VEGF-TKI showed a statistically significant higher degree of proteinuria compared to VEGF-TKI alone. There was no statistically significant difference in rates of hypertension between ICI-TKI and VEGF-TKI alone, but VEGF-TKI alone was statistically significantly more associated with hypertension than immunotherapy alone. Other renal toxicities, such as an increase in creatinine, acute kidney injury (AKI) and nephritis, were uncommon and not consistently reported in each trial. Conclusions: Contemporary regimens for first-line treatment of mRCC are associated with a higher grade of proteinuria than VEGF-TKI alone, while VEGF-TKI is more associated with hypertension than an ICI-ICI combination. Description of many renal toxicities across the studies reported have been diverse and a standardized definition across clinical trials would be helpful to reliably interpret the data regarding nephrotoxicity in the setting of treatment of renal cell carcinoma.","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139173084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genomic and Transcriptomic Characteristics of Tumors of Patients with Metastatic Clear Cell Renal Cell Carcinoma Clinically Benefiting from First-Line Treatment with Ipilimumab Plus Nivolumab 伊匹单抗联合尼妥珠单抗一线治疗临床获益的转移性透明细胞肾细胞癌患者肿瘤的基因组和转录组特征

IF 1.2

Kidney Cancer Pub Date : 2023-12-18 DOI: 10.3233/kca-230011

N. Tripathi, L. Meza, N. Sayegh, Ameish Govindarajan, Sara A. Byron, Jiaming Zhang, B. Chigarira, Y. Jo, Z. Zengin, Haoran Li, G. Gebrael, A. Desai, N. Agarwal, U. Swami, B. Maughan, S. Pal

{"title":"Genomic and Transcriptomic Characteristics of Tumors of Patients with Metastatic Clear Cell Renal Cell Carcinoma Clinically Benefiting from First-Line Treatment with Ipilimumab Plus Nivolumab","authors":"N. Tripathi, L. Meza, N. Sayegh, Ameish Govindarajan, Sara A. Byron, Jiaming Zhang, B. Chigarira, Y. Jo, Z. Zengin, Haoran Li, G. Gebrael, A. Desai, N. Agarwal, U. Swami, B. Maughan, S. Pal","doi":"10.3233/kca-230011","DOIUrl":"https://doi.org/10.3233/kca-230011","url":null,"abstract":"Background: Ipilimumab plus nivolumab is approved as a first-line treatment for intermediate or poor risk metastatic renal cell carcinoma (mRCC). However, ∼35% of patients progress within six months on ipilimumab plus nivolumab, and no validated genomic biomarkers predict the benefit. In this study, we explore the genomic and transcriptomic differences among patients with clear cell mRCC patients who either did or did not experience clinical benefit from first-line ipilimumab plus nivolumab therapy. Method: Patients with clear cell mRCC intermediate or poor IMDC risk scores, with available tumor whole exome with/without transcriptome sequencing before starting systemic therapy were included. Patients who developed a complete response, partial response, or stable disease for at least six months after initiating treatment were categorized into the ‘clinical benefit’ group, whereas the rest were classified as ‘no clinical benefit.’ Genomic alteration frequencies between the groups were assessed with a chi-square test. Differentially expressed genes and gene sets were identified via DeSeq2 and GSEA v4.2.3, respectively. Result: 53 patients with clear cell mRCC (37 clinical benefit and 16 no clinical benefit) were eligible and included. No significant difference was found in the genomic alteration frequencies between these groups. Baseline tumor transcriptomic data were available for 14 patients (9 clinical benefit and 5 no clinical benefit). The apical surface and pathways downregulated by KRAS signaling were enriched in the clinical benefit group, whereas inflammatory pathways were enriched in the no clinical benefit group. Conclusion: These findings suggest that tumor specific gene expression as assessed by RNA sequencing could serve as a potential biomarker of response to ipilimumab plus nivolumab therapy.","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138995614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted Literature Review of Outcomes to Initial Systemic Therapy for Advanced/Metastatic Non-Clear Cell Renal Cell Carcinoma in Observational Studies 观察性研究中晚期/转移性非透明细胞肾细胞癌初始全身治疗结果的针对性文献综述

Kidney Cancer Pub Date : 2023-10-10 DOI: 10.3233/kca-230008

Shawna R. Calhoun, Manish Sharma, Chung-Han Lee

{"title":"Targeted Literature Review of Outcomes to Initial Systemic Therapy for Advanced/Metastatic Non-Clear Cell Renal Cell Carcinoma in Observational Studies","authors":"Shawna R. Calhoun, Manish Sharma, Chung-Han Lee","doi":"10.3233/kca-230008","DOIUrl":"https://doi.org/10.3233/kca-230008","url":null,"abstract":"Background: Non-clear cell renal cell carcinoma (nccRCC) is a diverse group of cancers that occurs in approximately 25% of patients with renal cell carcinoma. In the advanced/metastatic setting, survival in all nccRCC subtypes is considered poor, due to the inherent aggressiveness of these cancers, and a lack of effective systemic treatment options. Clinical trials of immune/targeted agents have predominantly focused on patients with ccRCC. There is no globally accepted standard of care for nccRCC; however, recently clinical trials have been initiated in this population. Objective: To perform a targeted literature review of published original observational studies reporting common real-world clinical outcomes (real-world overall response rate [rwORR], real-world progression free survival [rwPFS], real-world overall survival [rwOS]) in previously treatment naïve patients with advanced/metastatic nccRCC. Methods: A targeted search of MEDLINE and EMBASE was conducted per PRISMA guidelines to identify observational studies in previously treatment naïve patients with advanced/metastatic nccRCC. Publications with adequate information since 2010 and from select conferences since 2020 were considered. Results: 27 studies across 29 publications were identified. Sample sizes ranged from 7-1,573 across these studies with differences in nccRCC subtypes included and treatments received. Real-world ORR ranged from 0–37%, median rwPFS from 2–17 months, and median rwOS from 3–30 months, across 19, 17, and 24 studies, respectively. These outcomes also varied with receipt/type of treatment and demographic/clinical subgroups with outcomes tending to be worse in patients with papillary RCC compared to chromophobe RCC. Conclusions: Clinical outcomes varied, as patient populations, eligible histologies, treatments and methods were heterogeneous.","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136255237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fibrinogen Levels in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: Results of a Multicenter Prospective Trial 纳武单抗治疗转移性肾癌患者的纤维蛋白原水平:一项多中心前瞻性试验的结果

Kidney Cancer Pub Date : 2023-10-06 DOI: 10.3233/kca-230007

Ilya Tsimafeyeu, Gunel Musaeva, Igor Utyashev, Kristina Zakurdaeva, Ivan Gerk, Olshanskaya Anna, Samira Mahmudova, Nana Otkhozoria, Maria Volkova, Timur Mitin

{"title":"Fibrinogen Levels in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: Results of a Multicenter Prospective Trial","authors":"Ilya Tsimafeyeu, Gunel Musaeva, Igor Utyashev, Kristina Zakurdaeva, Ivan Gerk, Olshanskaya Anna, Samira Mahmudova, Nana Otkhozoria, Maria Volkova, Timur Mitin","doi":"10.3233/kca-230007","DOIUrl":"https://doi.org/10.3233/kca-230007","url":null,"abstract":"Background: Introduction of immune checkpoint inhibitors in the standard of care for metastatic renal cell carcinoma (mRCC) requires robust but yet simple biomarkers to predict efficacy of immunotherapy. Objective: The aim of this study was to evaluate the association between fibrinogen levels and efficacy of second-line therapy with nivolumab in mRCC. Methods: This is a prospective multicenter biomarker study. Fibrinogen levels were measured one week prior to second-line nivolumab therapy and six times monthly. A high fibrinogen level was defined as ≥5 g/L. Patients were divided into two cohorts: high (H) and normal (N) fibrinogen levels. The primary endpoint was overall survival (OS). Results: The median OS was 31.5 months (95% confidence interval [CI], 27.9 to 35.1) in cohort N vs. 20.9 months (95% CI, 18.1 to 23.7) in cohort H (hazard ratio [HR], 0.39; 98.5% CI, 0.21 to 0.7; P = 0.002). The median progression-free survival was 9.4 months (95% CI, 5.5 to 14.1) in cohort N and 4.0 months (95% CI, 2.9 to 5.1) in cohort H (HR, 0.65; 95% CI, 0.51 to 0.72; P < 0.001). The objective response rate was higher in N cohort (33% vs. 17% ; P = 0.012). No statistically significant changes of fibrinogen concentration during nivolumab therapy were found. Conclusion: The study demonstrated an association of hyperfibrinogenemia with worse clinical outcomes of second-line nivolumab monotherapy in patients with mRCC. Further validation of fibrinogen as a predictive biomarker for immunotherapy efficacy in patients with mRCC is warranted.","PeriodicalId":17823,"journal":{"name":"Kidney Cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135302194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0